Background and Aim: Intraductal papillary mucinous tumor (IPMT) of the pancreas can be divided into three clinically distinct subtypes: main duct type, branch duct type and mixed type. Although it ...

By contrast, nodular lesions project directly into the lumen of the bile duct. The papillary subtype is the rarest form of perihilar CCA, and these lesions are typically friable and do not invade ...

Collecting duct carcinoma (CDC) is a rare and aggressive subtype of ... Renal medullary carcinoma, ccRCC, type 2 papillary RCC, and chromophobe RCC were included as comparators. To verify mutations of ...

Intraductal papillary (IPNB) and tubulopapillary (ITPN) neoplasms of the bile duct have been described as precursor lesions of CCA. The genetic and epigenetic alterations involved in the stepwise ...

1Department of Surgery, Duke University, Durham, North Carolina. 2Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan. 3Department of Computational Medicine and ...

3 Graduate School of Public Health, St Luke’s International University, Tokyo, Japan Objective Current guidelines recommend long-term image-based surveillance for patients with low-risk intraductal ...

Sorry, but nothing matched your search terms. Please try again with some different keywords.

The main supervisor is Ivan Shabo. My thesis is about prognostic factors in papillary thyroid cancer, which is the most common type of cancer in the thyroid gland. Today, treatment with surgery ...

Anktiva plus BCG aims to treat BCG-unresponsive NMIBC with papillary disease, potentially reducing radical cystectomy need. The treatment showed high rates of surgery avoidance and disease-free ...

ImmunityBio, Inc, a leading immunotherapy company, announced that it has completed multiple submissions to the US FDA including an sBLA for BCG-unresponsive NMIBC in papillary disease and an EAP for ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has completed multiple submissions to the FDA including an sBLA for BCG-unresponsive NMIBC in papillary ...